Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies

BACKGROUND: RAS/RAF/MAPK activation (mutational or non-mutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane binding pr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Lymphoma Myeloma Leuk
Huvudupphovsmän: Badar, Talha, Cortes, Jorge E, Ravandi, Farhad, O’Brien, Susan, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Borthakur, Gautam
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4509631/
https://ncbi.nlm.nih.gov/pubmed/25795639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.02.018
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk